A new randomised controlled trial published in The Lancet Regional Health – Europe offers three critical insights for managing post-COVID syndrome. First, immunoadsorption therapy demonstrated no significant symptom reduction compared to sham treatment, suggesting this blood filtration approach may not provide therapeutic benefit. Second, the rigorous methodology involved 60 patients across multiple German medical centres, strengthening confidence in these negative findings.
Third, these results meaningfully challenge the clinical rationale for incorporating blood filtration therapies into post-COVID treatment protocols. While autoimmune hypotheses initially motivated immunoadsorption research, this first randomised evidence does not support its use. For clinicians, this finding emphasises the importance of evidence-based decision-making in an area where unproven treatments remain tempting.
For patients seeking long COVID treatments, these results underscore the necessity of pursuing interventions backed by rigorous clinical trials. Read the full article on GMJ Newsroom.
Was this article helpful?
